|
|
|
Volumn 19, Issue 107, 2010, Pages 109-112
|
|
Liraglutide: Type 2 diabetes: More prudent to continue using exenatide
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ATORVASTATIN;
DIGOXIN;
ETHINYLESTRADIOL PLUS LEVONORGESTREL;
EXENDIN 4;
GLIMEPIRIDE;
GRISEOFULVIN;
HEMOGLOBIN A1C;
INSULIN;
INSULIN GLARGINE;
LIRAGLUTIDE;
LISINOPRIL;
METFORMIN;
PARACETAMOL;
PLACEBO;
ROSIGLITAZONE;
DRUG DERIVATIVE;
GLUCAGON LIKE PEPTIDE 1;
PEPTIDE;
SULFONYLUREA DERIVATIVE;
VENOM;
ANOREXIA;
ANTIBODY PRODUCTION;
BODY MASS;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
CONSTIPATION;
DIABETIC PATIENT;
DIARRHEA;
DRUG EFFICACY;
DRUG METABOLISM;
DRUG SURVEILLANCE PROGRAM;
DYSPEPSIA;
GLYCEMIC CONTROL;
HUMAN;
HYPOGLYCEMIA;
INCIDENCE;
KIDNEY DYSFUNCTION;
MEDICAL PRACTICE;
NAUSEA;
NON INSULIN DEPENDENT DIABETES MELLITUS;
NONHUMAN;
PANCREATITIS;
PATIENT MONITORING;
RECOMMENDED DRUG DOSE;
RISK BENEFIT ANALYSIS;
SHORT SURVEY;
SIDE EFFECT;
SINGLE DRUG DOSE;
TERATOGENICITY;
THERAPY EFFECT;
VOMITING;
WEIGHT REDUCTION;
ANIMAL;
CHEMICALLY INDUCED DISORDER;
REVIEW;
THYROID TUMOR;
ANIMALS;
CLINICAL TRIALS AS TOPIC;
DIABETES MELLITUS, TYPE 2;
GLUCAGON-LIKE PEPTIDE 1;
HUMANS;
PEPTIDES;
SULFONYLUREA COMPOUNDS;
THYROID NEOPLASMS;
VENOMS;
|
|
EID: 77956419255
PISSN: 11677422
EISSN: None
Source Type: Journal
DOI: None Document Type: Short Survey |
|
Times cited : (5)
|
|
References (9)
|
